Boston Scientific has signed a definitive agreement with SERB’s affiliates, Stark International and SERB SAS, to divest its BTG Specialty Pharmaceuticals business for $800m in cash.
Recipharm?has signed and closed an agreement with?SERB SA?(“SERB”) on a divestment of its rights to its potassium iodide product ThyroSafe? except for the US territory.?